2020
Impact of menthol on nicotine intake and preference in mice: Concentration, sex, and age differences
Bagdas D, Jackson A, Carper M, Chen RY, Akinola LS, Damaj MI. Impact of menthol on nicotine intake and preference in mice: Concentration, sex, and age differences. Neuropharmacology 2020, 179: 108274. PMID: 32827516, PMCID: PMC7572603, DOI: 10.1016/j.neuropharm.2020.108274.Peer-Reviewed Original ResearchConceptsOral nicotine consumptionEffect of mentholImpact of mentholNicotine consumptionFemale miceNicotine intakeΑ7 nicotinic acetylcholine receptorMenthol concentrationNicotine solutionHigher nicotine intakeAdolescent female miceMale C57BL/6J miceTwo-bottle choice paradigmWild-type miceNicotinic acetylcholine receptorsConcentration-dependent mannerOral nicotineC57BL/6J miceKO miceMale miceType miceMouse modelAcetylcholine receptorsHigh menthol concentrationAdult counterparts
2019
Assessing nicotine dependence using an oral nicotine free-choice paradigm in mice
Bagdas D, Diester C, Riley J, Carper M, Alkhlaif Y, AlOmari D, Alayoubi H, Poklis J, Damaj M. Assessing nicotine dependence using an oral nicotine free-choice paradigm in mice. Neuropharmacology 2019, 157: 107669. PMID: 31220484, PMCID: PMC6697382, DOI: 10.1016/j.neuropharm.2019.107669.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBehavior, AddictiveChoice BehaviorDose-Response Relationship, DrugDrug InteractionsFemaleMaleMiceMice, KnockoutNicotineNucleus AccumbensQuinineReceptors, NicotinicSelf AdministrationSex CharacteristicsSubstance Withdrawal SyndromeTobacco Use DisorderTyrosine 3-MonooxygenaseVareniclineConceptsAddictive-like propertiesNicotine intakeOral nicotine consumptionNicotine consumptionFree-choice paradigmNicotine solutionΑ6 KO miceTwo-bottle free-choice paradigmTyrosine hydroxylase levelsNicotinic acetylcholine receptor subunitsPartial agonist vareniclineOral nicotine intakeAbsence of nicotineAcetylcholine receptor subunitsΑ5 nAChRAdult C57BL/6JNicotine withdrawalKO miceFemale miceAgonist vareniclineDBA/2J miceHydroxylase levelsNicotine dependenceBinge drinkingObserved sex differences
2018
Blockade of nicotinic acetylcholine receptor enhances the responsiveness to bupropion in the mouse forced swim test
Bagdas D, AlSharari S, Roni M, Campbell V, Muldoon P, Carroll F, Damaj M. Blockade of nicotinic acetylcholine receptor enhances the responsiveness to bupropion in the mouse forced swim test. Behavioural Brain Research 2018, 360: 262-269. PMID: 30552947, PMCID: PMC6324988, DOI: 10.1016/j.bbr.2018.12.027.Peer-Reviewed Original ResearchConceptsAntidepressant-like effectsImmobility timeWT miceDecreased immobility timeDihydro-β-erythroidineAdult male miceWild-type miceEffects of β2Nicotinic acetylcholine receptorsBaseline immobilityAntidepressant effectsPresent studyJ miceKO miceSwim testMale miceWT littermatesRole of α4Bupropion administrationBupropionAcute dosesFST behaviorTransgenic miceAcetylcholine receptorsNAChR subunitsNew insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice
Bagdas D, Alkhlaif Y, Jackson A, Carroll FI, Ditre JW, Damaj MI. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology 2018, 138: 72-79. PMID: 29860196, PMCID: PMC6054891, DOI: 10.1016/j.neuropharm.2018.05.025.Peer-Reviewed Original ResearchConceptsEffects of vareniclineNicotine withdrawal signsNicotine rewardΑ5 nAChRWithdrawal signsHigh doseKnockout miceΒ2-nAChRsNicotine withdrawal-induced hyperalgesiaAdministration of vareniclineWithdrawal-induced hyperalgesiaΑ7 knockout miceDose-related mannerNicotinic acetylcholine receptorsΑ5 knockout micePlace preference testVarenicline doseCessation treatmentNicotine withdrawalSomatic signsVareniclineΑ7 nAChRsMouse modelCPP testNicotinic subtypesMonoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy
Curry Z, Wilkerson J, Bagdas D, Kyte S, Patel N, Donvito G, Mustafa M, Poklis J, Niphakis M, Hsu K, Cravatt B, Gewirtz D, Damaj M, Lichtman A. Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy. Journal Of Pharmacology And Experimental Therapeutics 2018, 366: jpet.117.245704. PMID: 29540562, PMCID: PMC6038031, DOI: 10.1124/jpet.117.245704.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsApoptosisBenzodioxolesBiomarkersCarbamatesCell Line, TumorCell ProliferationChemokine CCL2Disease Models, AnimalDose-Response Relationship, DrugEnzyme InhibitorsHumansHyperalgesiaInflammationMaleMiceMonoacylglycerol LipasesNociceptionP38 Mitogen-Activated Protein KinasesPaclitaxelPhosphoproteinsPiperidinesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2SuccinimidesConceptsAntinociceptive effectPaclitaxel-induced mechanical allodyniaPaclitaxel-induced neuropathic painH460 non-small cell lung cancer cellsNon-small cell lung cancer cellsMonoacylglycerol lipaseMonocyte chemoattractant protein-1Chemotherapy-induced neuropathyPaclitaxel-induced allodyniaPain side effectsPrimary hydrolytic enzymesCell lung cancer cellsSpinal dorsal hornDorsal root gangliaChemoattractant protein-1Novel pharmacologic strategiesPaclitaxel-treated animalsNumerous rodent modelsLung cancer cellsPlace preference paradigmMonoacylglycerol lipase inhibitorsIntrinsic rewarding effectsPhospho-p38 MAPKMechanical allodyniaNeuropathic pain
2016
The α7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain
Bagdas D, Wilkerson J, Kulkarni A, Toma W, AlSharari S, Gul Z, Lichtman A, Papke R, Thakur G, Damaj M. The α7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain. British Journal Of Pharmacology 2016, 173: 2506-2520. PMID: 27243753, PMCID: PMC4959951, DOI: 10.1111/bph.13528.Peer-Reviewed Original ResearchConceptsPositive allosteric modulatorsNeuropathic painPain modelAntinociceptive effectSpinal cordTail flickChronic constriction injury (CCI) neuropathic pain modelAllosteric agonistDose-dependent antinociceptive effectΑ7 nicotinic ACh receptorsGlial fibrillary acidic proteinNeuropathic pain modelAstrocyte-specific glial fibrillary acidic proteinInflammatory pain modelAcetic acid injectionHot-plate assayEffective pharmacological strategiesNicotinic ACh receptorsNovel therapeutic approachesFibrillary acidic proteinDorsal hornFormalin testPain modulationSubchronic administrationLocus of actionProtective Effects of Chlorogenic Acid and its Metabolites on Hydrogen Peroxide-Induced Alterations in Rat Brain Slices: A Comparative Study with Resveratrol
Gul Z, Demircan C, Bagdas D, Buyukuysal R. Protective Effects of Chlorogenic Acid and its Metabolites on Hydrogen Peroxide-Induced Alterations in Rat Brain Slices: A Comparative Study with Resveratrol. Neurochemical Research 2016, 41: 2075-2085. PMID: 27161374, DOI: 10.1007/s11064-016-1919-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntioxidantsBrainChlorogenic AcidDose-Response Relationship, DrugFemaleHydrogen PeroxideNeuroprotective AgentsOrgan Culture TechniquesRatsRats, Sprague-DawleyResveratrolStilbenesConceptsOxidative stress parametersCortical slicesRat brain slicesRat cortical slicesStress parametersChlorogenic acidChloride stainingProtective effectBrain slicesOxidative stressQuinic acidResveratrolNatural phenolic compoundsMain metaboliteMalondialdehydeCaffeic acidROS levelsIncubation mediumPhenolic compoundsAlterationsIC50 valuesPresent studyStainingΜM H2O2Oxygen speciesDiacylglycerol lipase β inhibition reverses nociceptive behaviour in mouse models of inflammatory and neuropathic pain
Wilkerson J, Ghosh S, Bagdas D, Mason B, Crowe M, Hsu K, Wise L, Kinsey S, Damaj M, Cravatt B, Lichtman A. Diacylglycerol lipase β inhibition reverses nociceptive behaviour in mouse models of inflammatory and neuropathic pain. British Journal Of Pharmacology 2016, 173: 1678-1692. PMID: 26915789, PMCID: PMC4842918, DOI: 10.1111/bph.13469.Peer-Reviewed Original ResearchConceptsChronic constrictive injuryNeuropathic pain modelWild-type miceAllodynic responsesInflammatory painPain modelLPS modelSide effectsExpression of LPSDiscernible side effectsUntoward side effectsPro-inflammatory responseEvidence of toleranceSites of inflammationConstrictive injuryMechanical allodyniaIntraplantar injectionNeuropathic painPathological painInflammatory mediatorsMouse peritoneal macrophagesLocus of actionNociceptive behaviorSciatic nerveAllodynia
2014
Pharmacologic overview of systemic chlorogenic acid therapy on experimental wound healing
Bagdas D, Gul N, Topal A, Tas S, Ozyigit M, Cinkilic N, Gul Z, Etoz B, Ziyanok S, Inan S, Turacozen O, Gurun M. Pharmacologic overview of systemic chlorogenic acid therapy on experimental wound healing. Naunyn-Schmiedeberg's Archives Of Pharmacology 2014, 387: 1101-1116. PMID: 25129377, DOI: 10.1007/s00210-014-1034-9.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-Inflammatory AgentsAntioxidantsChlorogenic AcidDose-Response Relationship, DrugFree Radical ScavengersLipid PeroxidationMaleNitric OxideOxidative StressRatsRats, Sprague-DawleySkinWound HealingConceptsSide effectsWound healingHigh doseBone marrowEffects of CGAAnti-inflammatory effectsDietary chlorogenic acidNitric oxide levelsMatrix metalloproteinase-9Oxidative stress markersPossible side effectsDose-dependent mannerChlorogenic acidCGA supplementationPharmacologic overviewFree radical scavengerAcid therapyCGA treatmentLeukocyte infiltrationPivotal organImmunohistochemical examinationRat bone marrowMetalloproteinase-9Oxide levelsStress markersEffects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice
Bagdas D, Muldoon P, Zhu A, Tyndale R, Damaj M. Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology 2014, 85: 67-72. PMID: 24859605, PMCID: PMC4106981, DOI: 10.1016/j.neuropharm.2014.05.006.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnxietyAryl Hydrocarbon HydroxylasesConditioning, PsychologicalCytochrome P450 Family 2Disease Models, AnimalDose-Response Relationship, DrugEnzyme InhibitorsHyperalgesiaMaleMecamylamineMethoxsalenMice, Inbred ICRMotor ActivityNicotineNicotinic AgonistsNicotinic AntagonistsRewardSeverity of Illness IndexSubstance Withdrawal SyndromeTobacco Use DisorderConceptsNicotine plasma levelsWithdrawal signsPlasma levelsAdministration of methoxsalenEffect of methoxsalenNicotine dependence behaviorsNicotine replacement therapyChronic nicotine infusionDependence-related behaviorsDrug elimination ratePlace preference testMetabolism of nicotineReward-like propertiesLack of enhancementSpontaneous withdrawalNicotine withdrawalReplacement therapyNicotine preferenceLow doseHigh doseNicotine infusionMouse CYP2A5CPP testActive nicotineNicotine levels
2013
Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain.
Kanat O, Bagdas D, Ozboluk H, Gurun M. Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain. JBUON 2013, 18: 1012-8. PMID: 24344031.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesicsAnimalsCytidine Diphosphate CholineDisease Models, AnimalDose-Response Relationship, DrugGABA-B Receptor AntagonistsHyperalgesiaInjections, IntraventricularMaleNeuralgiaNeurotransmitter Uptake InhibitorsNicotinic AntagonistsOrganoplatinum CompoundsOxaliplatinPain ThresholdRatsRats, Sprague-DawleyTime FactorsConceptsAntihyperalgesic effectNeuropathic painCDP-cholineNonselective muscarinic receptor antagonist atropineNonselective opioid receptor antagonist naloxoneRat paw pressure testReceptor antagonist CGP 35348Muscarinic receptor antagonist atropineNicotinic receptor antagonist mecamylamineOpioid receptor antagonist naloxoneOxaliplatin-induced neuropathic painCholine uptake inhibitor hemicholinium-3Induction of neuropathyAntagonist CGP 35348Paw pressure testGamma-amino butyric acidNicotinic acetylcholine receptorsCGP 35348Neuropatic painMechanical hyperalgesiaAntagonist atropineTime-dependent mannerPreclinical evidenceAntagonist naloxoneAntihyperalgesic activity
2011
The antihyperalgesic effect of cytidine-5′-diphosphate-choline in neuropathic and inflammatory pain models
Bagdas D, Sonat F, Hamurtekin E, Sonal S, Gurun M. The antihyperalgesic effect of cytidine-5′-diphosphate-choline in neuropathic and inflammatory pain models. Behavioural Pharmacology 2011, 22: 589-598. PMID: 21836465, DOI: 10.1097/fbp.0b013e32834a1efb.Peer-Reviewed Original ResearchConceptsNeuropathic pain modelAntihyperalgesic effectPain modelChronic constriction injury-induced neuropathic pain modelNonselective muscarinic receptor antagonist atropineNonselective opioid receptor antagonist naloxoneΓ-aminobutyric acid B receptorsNicotinic ACh receptor antagonistsReceptor antagonist CGP 35348Muscarinic receptor antagonist atropineNicotinic receptor antagonist mecamylamineOpioid receptor antagonist naloxoneCholine uptake inhibitor hemicholinium-3CDP-cholineEffect of intracerebroventricularlyAntagonist CGP 35348Central opioid receptorsInflammatory pain modelACh receptor antagonistNicotinic ACh receptorsCGP 35348Mechanical hyperalgesiaNeuropathic painAntagonist atropineAntagonist naloxone